Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Oct 2018 Planned End Date changed from 13 Sep 2019 to 30 Sep 2021.
- 05 Oct 2018 Planned primary completion date changed from 13 Sep 2019 to 30 Sep 2021.
- 31 Aug 2018 Biomarkers information updated